Related Experiment Video
Updated: Oct 1, 2025

Homochronic Transplantation of Interneuron Precursors into Early Postnatal Mouse Brains
Published on: June 8, 2018
Time to Transplant in X-Linked Adrenoleukodystrophy
Joshua L Bonkowsky1, Jacob Wilkes2
1University of Utah School of Medicine; Primary Children's Hospital, 7061Intermountain Healthcare, Salt Lake City, Utah, USA.
Insights
Time to hematopoietic stem cell transplantation for cerebral adrenoleukodystrophy averaged 97 days, with variations by race and hospital. Early transplant is crucial for improved outcomes in this rare neurological disease.
Area of Science:
- Neurology
- Hematology
- Pediatric Medicine
Background:
- Cerebral X-linked adrenoleukodystrophy (cALD) is a fatal inflammatory brain demyelination.
- Hematopoietic stem cell transplantation (HSCT) offers improved survival for cALD patients.
- Early HSCT, guided by MRI, is critical for better outcomes.
Purpose of the Study:
- To determine the average time from diagnosis of cALD to HSCT.
- To identify factors influencing the time to HSCT for cALD.
Main Methods:
- Retrospective review of pediatric patients (≤18 years) diagnosed with adrenoleukodystrophy.
- Utilized a nationwide administrative healthcare database (2015-2021).
- Calculated time from index brain MRI to HSCT code.
Main Results:
- Identified 27 cALD patients with total charges of $53 million.
- Average time to HSCT was 97 days.
- Hispanic patients (117 days) had longer wait times than White, non-Hispanic patients (80 days).
- Significant hospital-based variability in HSCT wait times was observed.
Conclusions:
- Time to HSCT for cALD exceeded 3 months in evaluated hospitals.
- Disparities in HSCT wait times exist based on race/ethnicity and hospital.
- Opportunities to reduce HSCT wait times for cALD patients are suggested.
Objectives:
Cerebral X-linked adrenoleukodystrophy (cALD) is an inflammatory demyelination of the brain that can lead to death unless treated by hematopoietic stem cell transplantation. Survival and improved outcomes for cerebral adrenoleukodystrophy are associated with hematopoietic stem cell transplantation at earliest evidence of disease on magnetic resonance imaging (MRI). Our goal was to determine average duration between diagnosis of cALD and hematopoietic stem cell transplantation.
Methods:
This was a retrospective review of data of patients aged 18 years or younger, using a nationwide administrative health care database (Pediatric Health Information System), with an International Classification of Diseases, Tenth Revision (ICD-10) diagnosis of adrenoleukodystrophy. Time range was October 1, 2015, through June 30, 2021. We determined time to hematopoietic stem cell transplantation by duration between index brain MRI and a code for hematopoietic stem cell transplantation.
Results:
We identified 27 patients with cerebral adrenoleukodystrophy. Total charges for the cohort was $53 million. Time to transplant averaged 97 days. For Hispanic patients, time to transplant was 117 days, compared with 80 days for White, non-Hispanic patients. Comparison of different hospitals showed significant variability in time to hematopoietic stem cell transplantation.
Discussion:
We found that time to hematopoietic stem cell transplantation was >3 months for patients with cerebral adrenoleukodystrophy in the hospitals we evaluated. We noted differences in average time by race/ethnicity and by hospital. Our findings suggest opportunity to reduce time to transplant in cerebral adrenoleukodystrophy.
More Related Videos
05:00Transplantation of Human Stem Cell-Derived GABAergic Neurons into the Early Postnatal Mouse Hippocampus to Mitigate Neurodevelopmental Disorders
Published on: November 11, 2022
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Related Concept Videos
Kidney Transplant I: Introduction
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Kidney Transplant II: Surgical Procedure